AU2004208848A1 - Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins - Google Patents

Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins Download PDF

Info

Publication number
AU2004208848A1
AU2004208848A1 AU2004208848A AU2004208848A AU2004208848A1 AU 2004208848 A1 AU2004208848 A1 AU 2004208848A1 AU 2004208848 A AU2004208848 A AU 2004208848A AU 2004208848 A AU2004208848 A AU 2004208848A AU 2004208848 A1 AU2004208848 A1 AU 2004208848A1
Authority
AU
Australia
Prior art keywords
protein
antigenic
acute phase
cells
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004208848A
Other languages
English (en)
Inventor
Pramod K. Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut Health Center
Original Assignee
University of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut Health Center filed Critical University of Connecticut Health Center
Publication of AU2004208848A1 publication Critical patent/AU2004208848A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2004208848A 2003-02-04 2004-02-04 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins Abandoned AU2004208848A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44476803P 2003-02-04 2003-02-04
US60/444,768 2003-02-04
PCT/US2004/003861 WO2004069204A2 (en) 2003-02-04 2004-02-04 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins

Publications (1)

Publication Number Publication Date
AU2004208848A1 true AU2004208848A1 (en) 2004-08-19

Family

ID=32850927

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004208848A Abandoned AU2004208848A1 (en) 2003-02-04 2004-02-04 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins

Country Status (4)

Country Link
EP (1) EP1594535A4 (de)
AU (1) AU2004208848A1 (de)
CA (1) CA2515107A1 (de)
WO (1) WO2004069204A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781791A2 (de) * 2004-08-20 2007-05-09 Novo Nordisk A/S Hemopexin-fusionsproteine
US20120237535A1 (en) * 2009-09-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Therapeutic Compositions For The Treatment of HPV-Induced Diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
EP1286693A4 (de) * 2000-06-02 2005-07-13 Univ Connecticut Health Ct Komplexe aus alpha-2-makroglobulin und antigenen molekülen zur immuntherapie

Also Published As

Publication number Publication date
CA2515107A1 (en) 2004-08-19
EP1594535A4 (de) 2006-07-12
WO2004069204A3 (en) 2004-11-25
WO2004069204A2 (en) 2004-08-19
EP1594535A2 (de) 2005-11-16

Similar Documents

Publication Publication Date Title
US9352019B2 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
RU2375077C2 (ru) Использование белков теплового шока для повышения эффективности терапий антителами
US20060217298A1 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
CA2410903A1 (en) Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
JP2006514088A (ja) 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法
US20060140966A1 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
AU2004208848A1 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
US20060228328A1 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
AU2004208851A1 (en) Immunogenic CD91 ligand-antigenic molecule complexes and fusion proteins
AU2004220627A1 (en) Immunogenic CD19 ligand-antigenic molecule complexes and fusion proteins

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period